Fig. 2
From: SOX2 as a novel contributor of oxidative metabolism in melanoma cells
SOX2 silencing in A375-M6 melanoma cells alters the efficacy of the metabolic drugs 2-DG and Metformin. a) Quantification chart (upper panel) and representative pictures (lower panel) of Annexin V/PI analysis of A375-M6 treated for 24 h with the anti-glycolytic drug 2-DG (50 mM) under standard (pH 7.4) or acidic (pH 6.7) conditions. b) Quantification chart (upper panel) and representative pictures (lower panel) of Annexin V/PI analysis of A375-M6 treated for 24 h with the anti-OxPhos drug Metformin (10 mM) under standard (pH 7.4) or acidic (pH 6.7) conditions. *p < 0.05, **p < 0.01, ***p < 0.001, Two-way ANOVA (statistical analysis compares for each phase- early apoptosis, late apoptosis, and necrosis- siSOX2 versus the respective untreated or treated siCTRL). N = 3